Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.

Androgen receptor (AR) splice variants (SV) have been implicated in the development of metastatic castration resistant prostate cancer and resistance to AR targeting therapies including abiraterone and enzalutamide. Agents targeting AR-SV are urgently needed to test this hypothesis and further improve the outcome of patients suffering from this lethal disease.

Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Jun 21 [Epub ahead of print]

Adam Sharp, Jonathan Welti, Julian Blagg, Johann S de Bono

Prostate Cancer Targeted Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust., Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research., Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research., Prostate Cancer Targeted Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust .